FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

bruce hillner

Research Profile

Activities & Behaviors

Cost Benefit Analysis

Disorders

Geographic Areas

Concepts & Ideas

Chemicals & Drugs

Antineoplastic Agents

Procedures

Co-author Network

Publications

TOP 3
Tracy Onega; Barry A Siegel; Yunjie Song; Tor D Tosteson; Qianfei Wang; bruce hillner; Anna N A Tosteson
Geographic and sociodemographic disparities in PET use by Medicare beneficiaries with cancer.
Thomas J Smith; bruce hillner
A way forward on the medically appropriate use of white cell growth factors.
bruce hillner; Bruce Quinn; Anthony F Shields; Barry A Siegel; Fenghai Duan; Ilana F Gareen; Lucy Hanna; R Edward Coleman
Impact of 18F-FDG PET used after initial treatment of cancer: comparison of the National Oncologic PET Registry 2006 and 2009 cohorts.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of bruce hillner (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Tracy Onega; Barry A Siegel; Yunjie Song; Tor D Tosteson; Qianfei Wang; bruce hillner; Anna N A Tosteson
Geographic and sociodemographic disparities in PET use by Medicare beneficiaries with cancer.
Journal of the American College of Radiology : JACR 2012;9(9):635-42.
2012: Thomas J Smith; bruce hillner
A way forward on the medically appropriate use of white cell growth factors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(14):1584-7.
2012: bruce hillner; Bruce Quinn; Anthony F Shields; Barry A Siegel; Fenghai Duan; Ilana F Gareen; Lucy Hanna; R Edward Coleman
Impact of 18F-FDG PET used after initial treatment of cancer: comparison of the National Oncologic PET Registry 2006 and 2009 cohorts.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2012;53(5):831-7.
2012: bruce hillner; Thomas J Smith
Wiser use of dose-dense adjuvant therapy in breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(8):772-4.
2012: bruce hillner; Yunjie Song; Tracy Onega; Anna N Tosteson; David C Goodman; Tor D Tosteson; Barry A Siegel
Growth in the use of PET for six cancer types after coverage by medicare: additive or replacement?
Journal of the American College of Radiology : JACR 2012;9(1):33-41.
2011: Thomas J Smith; bruce hillner
Bending the cost curve in cancer care.
The New England journal of medicine 2011;364(21):2060-5.
2011: Catherine Van Poznak; Sarah Temin; Gary C Yee; Nora A Janjan; William E Barlow; J Sybil Biermann; Linda D Bosserman; Cindy Geoghegan; bruce hillner; Richard L Theriault; Dan S Zuckerman; Jamie H Von Roenn
American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(9):1221-7.
2011: bruce hillner; Barry A Siegel; Anthony F Shields; Fenghai Duan; Ilana F Gareen; Lucy Hanna; R Edward Coleman
Impact of dedicated brain PET on intended patient management in participants of the national oncologic PET Registry.
Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging 2011;13(1):161-5.
2011: bruce hillner; Thomas J Smith
Allocating cancer-directed expenditures: tensions between prevention, early detection and treatment is unnecessary.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 2011;188():1-9.
2010: Thomas J Smith; bruce hillner
Explaining marginal benefits to patients, when "marginal" means additional but not necessarily small.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(24):5981-6.
2010: Thomas J Smith; bruce hillner
Comment on pegylated liposomal Doxorubicin plus docetaxel in metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(8):e128; author reply e129-30.
2010: Thomas J Smith; bruce hillner
Concrete options and ideas for increasing value in oncology care: the view from one trench.
The oncologist 2010;15 Suppl 1():65-72.
2010: R Edward Coleman; bruce hillner; Anthony F Shields; Fenghai Duan; Denise A Merlino; Lucy G Hanna; Sharon Hartson Stine; Barry A Siegel
PET and PET/CT reports: observations from the National Oncologic PET Registry.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2010;51(1):158-63.
2009: bruce hillner; Thomas J Smith
Efficacy does not necessarily translate to cost effectiveness: a case study in the challenges associated with 21st-century cancer drug pricing.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(13):2111-3.
2009: bruce hillner; Barry A Siegel; Anthony F Shields; Dawei Liu; Ilana F Gareen; Lucy Hanna; Sharon Hartson Stine; R Edward Coleman
The impact of positron emission tomography (PET) on expected management during cancer treatment: findings of the National Oncologic PET Registry.
Cancer 2009;115(2):410-8.
2008: bruce hillner; Barry A Siegel; Anthony F Shields; Dawei Liu; Ilana F Gareen; Ed Hunt; R Edward Coleman
Relationship between cancer type and impact of PET and PET/CT on intended management: findings of the national oncologic PET registry.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2008;49(12):1928-35.
2008: bruce hillner; Barry A Siegel; Dawei Liu; Anthony F Shields; Ilana F Gareen; Lucy Hanna; Sharon Hartson Stine; R Edward Coleman
Impact of positron emission tomography/computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: initial results from the National Oncologic PET Registry.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(13):2155-61.
2008: Jill K J Gaidos; bruce hillner; Arun J Sanyal
A decision analysis study of the value of a liver biopsy in nonalcoholic steatohepatitis.
Liver international : official journal of the International Association for the Study of the Liver 2008;28(5):650-8.
2007: bruce hillner; Dawei Liu; R Edward Coleman; Anthony F Shields; Ilana F Gareen; Lucy Hanna; Sharon Hartson Stine; Barry A Siegel
The National Oncologic PET Registry (NOPR): design and analysis plan.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2007;48(11):1901-8.
2007: Donald A Podoloff; Ranjana Advani; Craig Allred; Al B Benson; Elizabeth Brown; Harold J Burstein; Robert W Carlson; R Edward Coleman; Myron S Czuczman; Dominique Delbeke; Stephen B Edge; David S Ettinger; Frederic W Grannis; bruce hillner; John M Hoffman; Krystyna Kiel; Ritsuko Komaki; Steven M Larson; David A Mankoff; Kenneth E Rosenzweig; John M Skibber; Joachim Yahalom; Jq Michael Yu; Andrew D Zelenetz
NCCN task force report: positron emission tomography (PET)/computed tomography (CT) scanning in cancer.
Journal of the National Comprehensive Cancer Network : JNCCN 2007;5 Suppl 1():S1-22; quiz S23-2.
2007: Matthew J Lindsay; Barry A Siegel; Sean R. Tunis; bruce hillner; Anthony F Shields; Brian P Carey; R Edward Coleman
The National Oncologic PET Registry: expanded medicare coverage for PET under coverage with evidence development.
AJR. American journal of roentgenology 2007;188(4):1109-13.
2007: bruce hillner; Thomas J Smith
Do the large benefits justify the large costs of adjuvant breast cancer trastuzumab?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(6):611-3.
2007: bruce hillner
Anastrozole had a better risk-benefit profile than tamoxifen as adjuvant treatment for breast cancer in postmenopausal women.
ACP journal club 2007;146(1):4.
2006: bruce hillner; Jeanne S Mandelblatt
Caring for older women with breast cancer: can observational research fill the clinical trial gap?
Journal of the National Cancer Institute 2006;98(10):660-1.
2005: bruce hillner; Deborah Schrag; Daniel J Sargent; Charlie S Fuchs; Richard M Goldberg
Cost-effectiveness projections of oxaliplatin and infusional fluorouracil versus irinotecan and bolus fluorouracil in first-line therapy for metastatic colorectal carcinoma.
Cancer 2005;104(9):1871-84.
2005: Stefanie S Jeffrey; Per Eystein Lønning; bruce hillner
Genomics-based prognosis and therapeutic prediction in breast cancer.
Journal of the National Comprehensive Cancer Network : JNCCN 2005;3(3):291-300.
2005: W Warren Suh; bruce hillner; Lori J Pierce; James A Hayman
Cost-effectiveness of radiation therapy following conservative surgery for ductal carcinoma in situ of the breast.
International journal of radiation oncology, biology, physics 2005;61(4):1054-61.
2005: Nancy J O Birkmeyer; Philip P Goodney; Therese A Stukel; bruce hillner; John D Birkmeyer
Do cancer centers designated by the National Cancer Institute have better surgical outcomes?
Cancer 2005;103(3):435-41.
2004: bruce hillner; Renuka Tunuguntla; Melvin Fratkin
Clinical decisions associated with positron emission tomography in a prospective cohort of patients with suspected or known cancer at one United States center.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(20):4147-56.
2004: bruce hillner
Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer.
Cancer 2004;101(6):1311-22.
2004: Daniel L Riddle; bruce hillner; Philip S Wells; Robert E Johnson; Heather J Hoffman; Wilhelm A Zuelzer
Diagnosis of lower-extremity deep vein thrombosis in outpatients with musculoskeletal disorders: a national survey study of physical therapists.
Physical therapy 2004;84(8):717-28.
2004: bruce hillner
Barriers to clinical trial enrollment: are state mandates the solution?
Journal of the National Cancer Institute 2004;96(14):1048-9.
2003: bruce hillner; James N Ingle; Rowan T Chlebowski; Julie R Gralow; Gary C Yee; Nora Janjan; Jane A Cauley; Brent A Blumenstein; Kathy S Albain; Allan Lipton; Susan Brown
American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(21):4042-57.
2003: Thomas J Smith; bruce hillner; Harry D Bear
Taking action on the volume-quality relationship: how long can we hide our heads in the colostomy bag?
Journal of the National Cancer Institute 2003;95(10):695-7.
2003: bruce hillner
Trends in clinical trials reports in common cancers between 1989 and 2000.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(9):1850-8.
2003: Lenore M Buckley; bruce hillner
A cost effectiveness analysis of calcium and vitamin D supplementation, etidronate, and alendronate in the prevention of vertebral fractures in women treated with glucocorticoids.
The Journal of rheumatology 2003;30(1):132-8.
2002: James R Berenson; bruce hillner; Robert A Kyle; Kenneth C Anderson; Allan Lipton; Gary C Yee; J Sybil Biermann
American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(17):3719-36.
2002: Richard R Love; Nguyen Ba Duc; D Craig Allred; Nguyen Cong Binh; Nguyen Van Dinh; Nguyen Ngoc Kha; Tran Van Thuan; Syed K Mohsin; Le Dinh Roanh; Hoang Xuan Khang; Trinh Luong Tran; Tran Tu Quy; Nguyen Van Thuy; Pham Nhu Thé; Ton That Cau; Nguyen Dinh Tung; Dang Thanh Huong; Le Minh Quang; Nguyen Ngoc Hien; Le Thuong; Tian-Zhen Shen; Ye Xin; Qian Zhang; Thomas C Havighurst; Yonghong Fred Yang; bruce hillner; David L DeMets
Oophorectomy and tamoxifen adjuvant therapy in premenopausal Vietnamese and Chinese women with operable breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(10):2559-66.
2001: bruce hillner
Is cancer care best at high-volume providers?
Current oncology reports 2001;3(5):404-9.
2001: Thomas J Smith; bruce hillner
Ensuring quality cancer care by the use of clinical practice guidelines and critical pathways.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(11):2886-97.
2001: bruce hillner; J M Kirkwood; S S Agarwala
Burden of illness associated with metastatic melanoma: an audit of 100 consecutive referral center cases.
Cancer 2001;91(9):1814-21.
2001: bruce hillner; D Radice
Cost-effectiveness analysis of exemestane compared with megestrol in patients with advanced breast carcinoma.
Cancer 2001;91(3):484-9.
2000: bruce hillner; J D Roberts
Role of perspective and other uncertainties in cost-effectiveness assessments in advanced prostate cancer.
Journal of the National Cancer Institute 2000;92(21):1704-6.
2000: bruce hillner; Thomas J Smith; Christopher E Desch
Hospital and physician volume or specialization and outcomes in cancer treatment: importance in quality of cancer care.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(11):2327-40.
2000: bruce hillner; S Agarwala; M R Middleton
Post hoc economic analysis of temozolomide versus dacarbazine in the treatment of advanced metastatic melanoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(7):1474-80.
2000: bruce hillner; James N Ingle; J R Berenson; Nora Janjan; Kathy S Albain; Allan Lipton; Gary C Yee; J Sybil Biermann; Rowan T Chlebowski; David G Pfister
American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(6):1378-91.
2000: James A Hayman; bruce hillner; J R Harris; Lori J Pierce; Jane C Weeks
Cost-effectiveness of adding an electron-beam boost to tangential radiation therapy in patients with negative margins after conservative surgery for early-stage breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(2):287-95.
2000: Thomas J Smith; bruce hillner
Tamoxifen should be cost-effective in reducing breast cancer risk in high-risk women.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(2):284-6.
2000: bruce hillner; Jane C Weeks; Christopher E Desch; Thomas J Smith
Pamidronate in prevention of bone complications in metastatic breast cancer: a cost-effectiveness analysis.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(1):72-9.
1999: Lynne T Penberthy; Sheldon M Retchin; MK McDonald; Donna K McClish; Christopher E Desch; G F Riley; Thomas J Smith; bruce hillner; C J Newschaffer
Predictors of Medicare costs in elderly beneficiaries with breast, colorectal, lung, or prostate cancer.
Health care management science 1999;2(3):149-60.
1999: Christopher E Desch; Lynne T Penberthy; bruce hillner; MK McDonald; Thomas J Smith; Andrea L Pozez; Sheldon M Retchin
A sociodemographic and economic comparison of breast reconstruction, mastectomy, and conservative surgery.
Surgery 1999;125(4):441-7.
1998: bruce hillner; T J Smith
Hospital volume and patient outcomes in major cancer surgery: a catalyst for quality assessment and concentration of cancer services.
JAMA : the journal of the American Medical Association 1998;280(20):1783-4.
1998: bruce hillner
Review of cost-effectiveness assessments of chemotherapy in adjuvant and advanced breast cancer.
Anti-cancer drugs 1998;9(10):843-7.
1998: bruce hillner; MK McDonald; Christopher E Desch; Thomas J Smith; Lynne T Penberthy; Sheldon M Retchin
A comparison of patterns of care of nonsmall cell lung carcinoma patients in a younger and Medigap commercially insured cohort.
Cancer 1998;83(9):1930-7.
1998: Niels Neymark; W Kiebert; K Torfs; linda davies; P Fayers; bruce hillner; R Gelber; G Guyatt; P Kind; D Machin; E Nord; David Osoba; D Revicki; Kevin Schulman; K Simpson
Methodological and statistical issues of quality of life (QoL) and economic evaluation in cancer clinical trials: report of a workshop.
European journal of cancer (Oxford, England : 1990) 1998;34(9):1317-33.
1998: bruce hillner
Cost-effectiveness assessment of interferon alfa-2b as adjuvant therapy of high-risk resected cutaneous melanoma.
European journal of cancer (Oxford, England : 1990) 1998;34 Suppl 3():S18-21.
1998: bruce hillner; T J Smith
Does a clinical trial warrant an economic analysis?
Journal of the National Cancer Institute 1998;90(10):724-5.
1998: bruce hillner; MK McDonald; Christopher E Desch; Thomas J Smith; Lynne T Penberthy; P Maddox; Sheldon M Retchin
Costs of care associated with non-small-cell lung cancer in a commercially insured cohort.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(4):1420-4.
1998: bruce hillner; Thomas J Smith
Overview of economic analysis of Le Chevalier Vinorelbine Study.
Oncology (Williston Park, N.Y.) 1998;12(3 Suppl 4):14-6; discussion 17.
1998: James A Hayman; bruce hillner; J R Harris; Jane C Weeks
Cost-effectiveness of routine radiation therapy following conservative surgery for early-stage breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(3):1022-9.
1997: bruce hillner
Decision analysis: MIBI imaging of nonpalpable breast abnormalities.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1997;38(11):1772-8.
1997: bruce hillner; J M Kirkwood
Economic analyses of benefit from interferon-alpha 2B in high-risk melanoma: trade-offs between completeness, simplicity and clarity.
European journal of cancer (Oxford, England : 1990) 1997;33(9):1345-6.
1997: bruce hillner; J M Kirkwood; M B Atkins; E R Johnson; Thomas J Smith
Economic analysis of adjuvant interferon alfa-2b in high-risk melanoma based on projections from Eastern Cooperative Oncology Group 1684.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(6):2351-8.
1997: Karen Antman; Philip Rowlings; WP Vaughan; CJ Pelz; Joseph W Fay; KK Fields; Cesar O Freytes; Robert Peter Gale; bruce hillner; H K Holland; M J Kennedy; John P Klein; Hillard M Lazarus; Philip L McCarthy; RA Saez; Gary Spitzer; Edward A Stadtmauer; Stephanie F Williams; Steven Neil Wolff; Kathleen A Sobocinski; James O Armitage; Mary M Horowitz
High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(5):1870-9.
1997: bruce hillner; MK McDonald; Lynne T Penberthy; Christopher E Desch; Thomas J Smith; P Maddux; W P Glasheen; Sheldon M Retchin
Measuring standards of care for early breast cancer in an insured population.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(4):1401-8.
1997: T J Smith; bruce hillner; R B Mitchell
Decision analysis in non-small-cell lung cancer: not back to the drawing modeling board, back to the bedside.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(3):870-2.
1997: Thomas J Smith; bruce hillner; Norbert Schmitz; D C Linch; P Dreger; A H Goldstone; M A Boogaerts; A Ferrant; H Link; A Zander; Saul Yanovich; R Kitchin; M H Erder
Economic analysis of a randomized clinical trial to compare filgrastim-mobilized peripheral-blood progenitor-cell transplantation and autologous bone marrow transplantation in patients with Hodgkin's and non-Hodgkin's lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(1):5-10.
1996: Charles L Bennett; T J Smith; Jane C Weeks; A B Bredt; J Feinglass; John H Fetting; bruce hillner; M R Somerfield; R J Winn
Use of hematopoietic colony-stimulating factors: the American Society of Clinical Oncology survey. The Health Services Research Committee of the American Society of Clinical Oncology.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(9):2511-20.
1996: bruce hillner
Genetic tests: a search for economy of scale.
American journal of human genetics 1996;59(2):287-8.
1996: Charles L Bennett; David B Matchar; D McCrory; D G McLeod; E D Crawford; bruce hillner
Cost-effective models for flutamide for prostate carcinoma patients: are they helpful to policy makers?
Cancer 1996;77(9):1854-61.
1996: bruce hillner; H D Bear; Laurie L Fajardo
Estimating the cost-effectiveness of stereotaxic biopsy for nonpalpable breast abnormalities: a decision analysis model.
Academic radiology 1996;3(4):351-60.
1996: bruce hillner; Thomas J Smith
Cost-effectiveness analysis of three regimens using vinorelbine (Navelbine) for non-small cell lung cancer.
Seminars in oncology 1996;23(2 Suppl 5):25-30.
1996: C E Desch; bruce hillner; Thomas J Smith
Economic considerations in the care of lung cancer patients.
Current opinion in oncology 1996;8(2):126-32.
1996: Christopher E Desch; Lynne T Penberthy; C J Newschaffer; bruce hillner; M Whittemore; Donna K McClish; Thomas J Smith; Sheldon M Retchin
Factors that determine the treatment for local and regional prostate cancer.
Medical care 1996;34(2):152-62.
1996: bruce hillner
Role of decision analysis in relation to clinical trials and a US perspective of the Battelle model.
PharmacoEconomics 1996;9 Suppl 2():30-6.
1996: bruce hillner; Lynne T Penberthy; Christopher E Desch; MK McDonald; Thomas J Smith; Sheldon M Retchin
Variation in staging and treatment of local and regional breast cancer in the elderly.
Breast cancer research and treatment 1996;40(1):75-86.
1996: bruce hillner
Estimating the cost-effectiveness of flutamide in metastatic cancer.
Cancer treatment reviews 1996;22 Suppl A():103-8.
1996: bruce hillner; Christopher E Desch; R W Carlson; Thomas J Smith; L Esserman; H D Bear
Trade-offs between survival and breast preservation for three initial treatments of ductal carcinoma-in-situ of the breast.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(1):70-7.
1995: Thomas J Smith; Lynne T Penberthy; Christopher E Desch; M Whittemore; C Newschaffer; bruce hillner; Donna K McClish; Sheldon M Retchin
Differences in initial treatment patterns and outcomes of lung cancer in the elderly.
Lung cancer (Amsterdam, Netherlands) 1995;13(3):235-52.
1995: bruce hillner; Thomas J Smith
Cost effectiveness and other assessments of adjuvant therapies for early breast cancer.
Oncology (Williston Park, N.Y.) 1995;9(11 Suppl):129-34.
1995: Thomas J Smith; bruce hillner; D M Neighbors; P A McSorley; T Le Chevalier
Economic evaluation of a randomized clinical trial comparing vinorelbine, vinorelbine plus cisplatin, and vindesine plus cisplatin for non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(9):2166-73.
1995: Charles L Bennett; T J Smith; S L George; bruce hillner; S Fleishman; H B Niell
Free-riding and the prisoner's dilemma: problems in funding economic analyses of phase III cancer clinical trials.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(9):2457-63.
1995: bruce hillner; D G McLeod; E D Crawford; Charles L Bennett
Estimating the cost effectiveness of total androgen blockade with flutamide in M1 prostate cancer.
Urology 1995;45(4):633-40.
1995: bruce hillner
Potential evaluation of the incremental cost-effectiveness of paclitaxel in advanced non-small-cell lung cancer (Eastern Cooperative Oncology Group 5592).
Journal of the National Cancer Institute. Monographs 1995;(19):65-7.
1994: Sheldon M Retchin; bruce hillner
The costs and benefits of a screening program to detect dementia in older drivers.
Medical decision making : an international journal of the Society for Medical Decision Making 1994;14(4):315-24.
1993: Thomas J Smith; bruce hillner; Christopher E Desch
Efficacy and cost-effectiveness of cancer treatment: rational allocation of resources based on decision analysis.
Journal of the National Cancer Institute 1993;85(18):1460-74.
1993: Christopher E Desch; bruce hillner; Thomas J Smith; Sheldon M Retchin
Should the elderly receive chemotherapy for node-negative breast cancer? A cost-effectiveness analysis examining total and active life-expectancy outcomes.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(4):777-82.
1993: Thomas J Smith; bruce hillner
The efficacy and cost-effectiveness of adjuvant therapy of early breast cancer in premenopausal women.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(4):771-6.
1993: bruce hillner
Financial costs, benefits, and patient risk preferences in node-negative breast cancer: insights from a decision analysis model.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 1993;127():277-84.
1993: bruce hillner; Thomas J Smith; Christopher E Desch
Assessing the cost effectiveness of adjuvant therapies in early breast cancer using a decision analysis model.
Breast cancer research and treatment 1993;25(2):97-105.
1992: bruce hillner; Thomas J Smith; Christopher E Desch
Efficacy and cost-effectiveness of autologous bone marrow transplantation in metastatic breast cancer. Estimates using decision analysis while awaiting clinical trial results.
JAMA : the journal of the American Medical Association 1992;267(15):2055-61.
1992: Christopher E Desch; M R Lasala; Thomas J Smith; bruce hillner
The optimal timing of autologous bone marrow transplantation in Hodgkin's disease patients after a chemotherapy relapse.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(2):200-9.
1992: bruce hillner; J T Philbrick; D M Becker
Optimal management of suspected lower-extremity deep vein thrombosis. An evaluation with cost assessment of 24 management strategies.
Archives of internal medicine 1992;152(1):165-75.
1992: bruce hillner; Thomas J Smith
A model of chemotherapy in node-negative breast cancer.
Journal of the National Cancer Institute. Monographs 1992;(11):143-9.
1992: bruce hillner; Thomas J Smith
Should women with node-negative breast cancer receive adjuvant chemotherapy?--Insights from a decision analysis model.
Breast cancer research and treatment 1992;23(1-2):17-27.
1991: bruce hillner; Thomas J Smith
Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer. A decision-analysis model.
The New England journal of medicine 1991;324(3):160-8.
1989: C M Clancy; bruce hillner
Physicians as gatekeepers. The impact of financial incentives.
Archives of internal medicine 1989;149(4):917-20.
1987: bruce hillner; R M Centor
What a difference a day makes: a decision analysis of adult streptococcal pharyngitis.
Journal of general internal medicine 1987;2(4):244-50.
1986: bruce hillner; J P Hollenberg; Stephen G Pauker
Postmenopausal estrogens in prevention of osteoporosis. Benefit virtually without risk if cardiovascular effects are considered.
The American journal of medicine 1986;80(6):1115-27.